MedPath

ong Term Administration Study of OPC-12759 Ophthalmic Suspensio

Phase 3
Conditions
Dry eye syndromes
Registration Number
JPRN-jRCT2080220651
Lead Sponsor
Otsuka Pharmaceuticals Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
153
Inclusion Criteria

1.Out patient;
2.Ocular discomfort severity is moderate to severe;
3.Cornaeal-conjunctival damage is moderate to severe;
4.Unanaesthetized Schirmer's test score of 5mm/5 minutes or less, or tear breakup time is 5 seconds or less;
5.Best corrected visual acuity of 0.2 or better in both eyes.

Exclusion Criteria

1.Presence of anterior segment disease or disorder other than that associated with keratoconjunctivitis scicca;
2.Ocular hypertension patient or glaucoma patient with ophthalmic solution;
3.Anticipated use of any topically-instilled ocular medications or patients who cannot discontinue the use during the study;
4.Anticipated use of contact lens during the study;
5.Patient with punctal plug;
6.Any history of ocular surgery within 12 months;
7.Female patients who are pregnant, possibly pregnant or breast feeding;
8.Known hypersensitivity to any component of the study drug or procedual medications;
9.Receipt of any investigational product within 4 months.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath